1. Home
  2. AVIR
  3. AVIR News

Latest Atea Pharmaceuticals Inc. (AVIR) News on October 31, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
AVIR

GlobeNewswire

9 days ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

Discovering Opportunities: Penny Stocks To Consider In October 2025
AVIR

Simply Wall St.

21 days ago

Discovering Opportunities: Penny Stocks To Consider In October 2025

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
AVIR

GlobeNewswire

24 days ago

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

June 2025's Promising Penny Stocks
AVIR

Simply Wall St.

4 months ago

June 2025's Promising Penny Stocks

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
AVIR

GlobeNewswire

4 months ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation
AVIR

Simply Wall St.

4 months ago

Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
AVIR

GOBankingRates

5 months ago

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

3 International Vacations That Are Cheaper Than an iPhone
AVIR

GOBankingRates

5 months ago

3 International Vacations That Are Cheaper Than an iPhone

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck
AVIR

GOBankingRates

5 months ago

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

This week in Trumponomics: Too bad TACO isn’t true
AVIR

Yahoo Finance

5 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right
AVIR

The Guardian

5 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF
AVIR

Yahoo Finance Video

5 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?
AVIR

Benzinga

5 months ago

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Ford recalls more than 29,000 vehicles in the US, NHTSA says
AVIR

Reuters

5 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Top Penny Stocks To Watch In May 2025
AVIR

Simply Wall St.

5 months ago

Top Penny Stocks To Watch In May 2025

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
AVIR

GlobeNewswire

6 months ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
AVIR

GlobeNewswire

6 months ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
AVIR

GlobeNewswire

6 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
AVIR

GlobeNewswire

6 months ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
AVIR

GlobeNewswire

6 months ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

AVIR

MT Newswires

7 months ago

Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
AVIR

GlobeNewswire

7 months ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
AVIR

GlobeNewswire

7 months ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

AVIR

MT Newswires

7 months ago

Sector Update: Health Care Stocks Retreat Wednesday Afternoon

AVIR

MT Newswires

7 months ago

Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting

AVIR

Business Wire

7 months ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Atea Pharmaceuticals Issues Statement Regarding Director Nominations
AVIR

GlobeNewswire

7 months ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory
AVIR

Insider Monkey

7 months ago

Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
AVIR

GlobeNewswire

7 months ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential
AVIR

Simply Wall St.

8 months ago

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

AVIR

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Atea Pharmaceuticals Inc Earnings Call

AVIR

GuruFocus.com

8 months ago

Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ...

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
AVIR

GlobeNewswire

8 months ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
AVIR

GlobeNewswire

8 months ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
AVIR

GlobeNewswire

8 months ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

February 2025 US Penny Stocks To Watch
AVIR

Simply Wall St.

9 months ago

February 2025 US Penny Stocks To Watch

AVIR

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 01/21/2025

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
AVIR

GlobeNewswire

10 months ago

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AVIR

GlobeNewswire

10 months ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

US Penny Stocks To Watch In December 2024
AVIR

Simply Wall St.

10 months ago

US Penny Stocks To Watch In December 2024

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
AVIR

GlobeNewswire

10 months ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir
AVIR

TipRanks

a year ago

Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
AVIR

Benzinga

a year ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Atea plans Phase 3 study for hepatitis C drug after mid-stage results
AVIR

BioPharma Dive

a year ago

Atea plans Phase 3 study for hepatitis C drug after mid-stage results

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Promising US Penny Stocks To Watch In November 2024
AVIR

Simply Wall St.

a year ago

Promising US Penny Stocks To Watch In November 2024

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
AVIR

Zacks

a year ago

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

AVIR

GuruFocus.com

a year ago

Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight
AVIR

Simply Wall St.

a year ago

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
AVIR

Zacks

a year ago

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

AVIR

GuruFocus.com

a year ago

Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...

Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AVIR

Zacks

a year ago

Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
AVIR

Zacks

a year ago

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
AVIR

Benzinga

a year ago

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus

AVIR

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

AVIR

MT Newswires

a year ago

Atea Pharmaceuticals' Phase 3 Study Assessing Bemnifosbuvir for COVID-19 Treatment Fails to Meet Primary Endpoint

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
AVIR

Zacks

a year ago

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway

All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
AVIR

Zacks

a year ago

All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
AVIR

Zacks

a year ago

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

AVIR

GuruFocus.com

a year ago

Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
AVIR

GlobeNewswire

a year ago

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
AVIR

GlobeNewswire

2 years ago

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
AVIR

GlobeNewswire

2 years ago

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
AVIR

Insider Monkey

2 years ago

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript

AVIR

GuruFocus.com

2 years ago

Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AVIR

GlobeNewswire

2 years ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
AVIR

GlobeNewswire

2 years ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Investors in York Water (NASDAQ:YORW) have unfortunately lost 15% over the last three years
AVIR

Simply Wall St.

2 years ago

Investors in York Water (NASDAQ:YORW) have unfortunately lost 15% over the last three years

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
AVIR

GlobeNewswire

2 years ago

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks
AVIR

StockStory

2 years ago

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks

Advertising Software Stocks Q3 Earnings: AppLovin (NASDAQ:APP) Best of the Bunch
AVIR

StockStory

2 years ago

Advertising Software Stocks Q3 Earnings: AppLovin (NASDAQ:APP) Best of the Bunch

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
AVIR

Zacks

2 years ago

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
AVIR

GlobeNewswire

2 years ago

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

AVIR

Business Wire

2 years ago

DTS AutoStage™ Expands into More Vehicle Models Following Video Launch, Developing New Functionality

AVIR

Business Wire

2 years ago

Xperi Expands its Global Footprint with its Powered by TiVo Media Platform for Smart TVs and Connected Car

How Diversified Energy blazed a trail for energy companies
AVIR

Yahoo Finance Video

2 years ago

How Diversified Energy blazed a trail for energy companies

Is It Time To Consider Buying LSB Industries, Inc. (NYSE:LXU)?
AVIR

Simply Wall St.

2 years ago

Is It Time To Consider Buying LSB Industries, Inc. (NYSE:LXU)?

Why Renewable Energy Stocks Plunged on Wednesday
AVIR

Motley Fool

2 years ago

Why Renewable Energy Stocks Plunged on Wednesday

TEGNA and NBC Renew Affiliation Agreement
AVIR

Business Wire

2 years ago

TEGNA and NBC Renew Affiliation Agreement

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AVIR

GlobeNewswire

2 years ago

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock
AVIR

GlobeNewswire

2 years ago

Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic
AVIR

GlobeNewswire

2 years ago

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

Safe Bulkers, Inc.'s (NYSE:SB) top owners are individual investors with 37% stake, while 26% is held by insiders
AVIR

Simply Wall St.

2 years ago

Safe Bulkers, Inc.'s (NYSE:SB) top owners are individual investors with 37% stake, while 26% is held by insiders

The Zacks Analyst Blog Highlights Assurant, Kinsale Capital Group and NMI Holdings
AVIR

Zacks

2 years ago

The Zacks Analyst Blog Highlights Assurant, Kinsale Capital Group and NMI Holdings

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools
AVIR

PR Newswire

2 years ago

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

Will Garmin Ltd. (GRMN) Face Stiffer Competition?
AVIR

Insider Monkey

2 years ago

Will Garmin Ltd. (GRMN) Face Stiffer Competition?

Modernize Unveils In-Depth Homeowner Insights Report: A Guide to Future-Proofing Your Business
AVIR

Business Wire

2 years ago

Modernize Unveils In-Depth Homeowner Insights Report: A Guide to Future-Proofing Your Business

Share on Social Networks: